Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19185
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBowyer, S-
dc.contributor.authorPrithviraj, Prashanth-
dc.contributor.authorLorigan, P-
dc.contributor.authorLarkin, J-
dc.contributor.authorMcArthur, G-
dc.contributor.authorAtkinson, V-
dc.contributor.authorMillward, M-
dc.contributor.authorKhou, M-
dc.contributor.authorDiem, S-
dc.contributor.authorRamanujam, S-
dc.contributor.authorKong, B-
dc.contributor.authorLiniker, E-
dc.contributor.authorGuminski, A-
dc.contributor.authorParente, P-
dc.contributor.authorAndrews, M C-
dc.contributor.authorParakh, S-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorLong, G V-
dc.contributor.authorCarlino, M S-
dc.contributor.authorKlein, O-
dc.date2016-04-28-
dc.date.accessioned2018-09-13T00:21:10Z-
dc.date.available2018-09-13T00:21:10Z-
dc.date.issued2016-05-10-
dc.identifier.citationBritish Journal of Cancer 2016; 114(10): 1084-1089-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19185-
dc.description.abstractRecent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses. Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient. Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.-
dc.language.isoeng-
dc.titleEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.-
dc.typeJournal Article-
dc.identifier.journaltitleBritish Journal of Cancer-
dc.identifier.affiliationRoyal Marsden Hospital NHS Foundation Trust, London, UKen
dc.identifier.affiliationThe Christie NHS Foundation Trust and University of Manchester, Manchester, UKen
dc.identifier.affiliationDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationWestmead Hospital, Sydney, New South Wales, Australiaen
dc.identifier.affiliationBox Hill Hospital, Box Hill, Victoria, Australiaen
dc.identifier.affiliationPrincess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationUniversity of Sydney, Sydney, New South Wales, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Medicine and Pharmacology, University of Western Australia, Australia, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationRockingham General Hospital, Cooloongup, Western Australia, Australiaen
dc.identifier.affiliationMelanoma Institute Australia, Sydney, New South Wales, Australiaen
dc.identifier.doi10.1038/bjc.2016.107-
dc.identifier.orcid0000-0002-3898-950X-
dc.identifier.pubmedid27124339-
dc.type.austinJournal Article-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.